A tale of two receptors: insulin and insulin-like growth factor signaling in cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25303978.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2056 and PMC identifier 4498265.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inhibition of the type I IGF receptor (IGF1R) has been the focus of numerous clinical trials. Two reports in this issue describe the results of phase I trials of an IGF1R tyrosine kinase inhibitor OSI-906. This commentary will describe the complex endocrine changes induced by these types of agents.
Medical subject headings
- Antineoplastic Agents
- Imidazoles
- Neoplasms
- Pyrazines